Majewska Anna, Lasek Witold, Janyst Michał, Młynarczyk Grazyna
Acta Pol Pharm. 2016 May-Jun;73(3):637-44.
Key issues in the development of novel antivirals are the emergence of resistant strains. The development of new drugs effective against herpes diseases has proven to be both difficult and time-consuming. Some alternative may be to optimize the efficacy and selectivity of existing antiviral drugs or combining them with other well known agents. Inosine pranobex exerts a direct antiviral effect as well as secondary effect to its immunomodulatory activity. We found that increasing concentrations of inosine pranobex (50-400 µg/mL) produced progressively growing inhibitory effect on HHV-1 replication, following infection of different cell lines. The combination of 1000 IU/mL IFN-α and inosine pranobex also resulted in enhanced anti-HHV activity. Immunotherapy may be beneficial for patients from whom strains resistant to currently known antiviral drugs have been isolated.
新型抗病毒药物研发中的关键问题是耐药菌株的出现。事实证明，开发有效的抗疱疹疾病新药既困难又耗时。一些替代方法可能是优化现有抗病毒药物的疗效和选择性，或将它们与其他知名药物联合使用。异丙肌苷具有直接抗病毒作用以及对其免疫调节活性的次要作用。我们发现，在感染不同细胞系后，增加异丙肌苷的浓度（50 - 400 µg/mL）对人疱疹病毒1型（HHV - 1）复制产生逐渐增强的抑制作用。1000 IU/mL的α干扰素与异丙肌苷联合使用也增强了抗HHV活性。免疫疗法可能对已分离出对目前已知抗病毒药物耐药菌株的患者有益。
